Tinnitus News and Research

Latest Tinnitus News and Research

Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Unlocking the first gene to cause otosclerosis: an interview with Dr Ralph Holme

Unlocking the first gene to cause otosclerosis: an interview with Dr Ralph Holme

Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

UK charity Action on Hearing Loss funds new project to develop medicines for hearing loss

UK charity Action on Hearing Loss funds new project to develop medicines for hearing loss

Researchers design more effective version of FDA-approved epilepsy drug with fewer side effects

Researchers design more effective version of FDA-approved epilepsy drug with fewer side effects

Concussion-related symptoms improve following initial session of OMT

Concussion-related symptoms improve following initial session of OMT

Brain's natural plasticity could compensate for inner ear damage

Brain's natural plasticity could compensate for inner ear damage

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

New study reveals why some vestibular schwannomas cause hearing loss

New study reveals why some vestibular schwannomas cause hearing loss

New study reveals link between tinnitus severity and emotion processing in the brain

New study reveals link between tinnitus severity and emotion processing in the brain

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Breakthrough research to be presented at AAO-HNSF 2015 Annual Meeting & OTO EXPO

Breakthrough research to be presented at AAO-HNSF 2015 Annual Meeting & OTO EXPO

Neuroscientists reveal the brain malady responsible for tinnitus, chronic pain

Neuroscientists reveal the brain malady responsible for tinnitus, chronic pain

NEI experts explore long-term effects of Ebola on the eye

NEI experts explore long-term effects of Ebola on the eye

Pitt researchers identify molecular mechanisms behind resilience to tinnitus, possible drug therapy

Pitt researchers identify molecular mechanisms behind resilience to tinnitus, possible drug therapy

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Transcranial magnetic stimulation holds promise for tinnitus patients

Transcranial magnetic stimulation holds promise for tinnitus patients

New research project aims to improve music listening experiences in people with hearing impairments

New research project aims to improve music listening experiences in people with hearing impairments

Major breakthrough provides new insights into how tinnitus develops

Major breakthrough provides new insights into how tinnitus develops

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.